Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
The European Society of Cardiology is aware that Sanofi Aventis has discontinued its phase IIIb PALLAS trial, which evaluated dronedarone vs placebo in patients with permanent atrial fibrillation and at least one other cardiovascular factor (a population different from the population with non-permanent AF for which dronedarone is currently approved).
The decision was taken as a significant increase in cardiovascular events in the dronedarone arm was observed.
Sanofi has informed regulatory authorities of this decision and the European Medicines Agency (EMA) is reviewing the overall benefit/risk profile of dronedarone.
The ESC is studying the new data available. Patients currently taking dronedarone should not stop their therapy and should consult their treating physician should they have any questions.
EMA Press Release (11 July 2011)
Sanofi Press Release (7 July 2011) Statement by the US Food and Drug Administration (FDA) (21 July 2011)
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved